RUFINO C. PABICO, M.D.; R. GORDON DOUGLAS, M.D., F.A.C.P.; ROBERT F. BETTS, M.D.; BARBARA A. McKENNA, M.S.; RICHARD B. FREEMAN, M.D., F.A.C.P.
Thirty renal transplant recipients received 0.5 ml of Influenza Virus Vaccine, Bivalent, USP, intramuscularly. Serum hemagglutination-inhibiting and nasal secretory neutralizing antibodies were measured before and 3 to 4 weeks after vaccination. Creatinine clearance and urinary protein excretion were measured before and weekly for 4 to 8 weeks after vaccination. Ten of 13 patients (77%) with creatinine clearance of ≥ 70 ml/min·1.73m2 (group I) had ≥ a fourfold increase in hemagglutination-inhibiting antibody titers to influenza A or B virus after vaccination, while only six of 17 patients (35%) with creatinine clearance of < 70 ml/min·1.73m2 (group II) had a similar increase (chi-square = 5.129; P < 0.05). Six of 13 patients (46%) in group I had ≥ a fourfold increase in neutralizing antibody titers to influenza A or B virus after vaccination, whereas none in group II had a similar increase (chi-square = 7.135; P < 0.01). There were no adverse effects on the allografts. Only minor side effects were noted in a few patients. Because of its safety and antigenicity, influenza vaccination should be offered to renal transplant recipients particularly during threats of epidemic outbreaks.
PABICO RC, DOUGLAS RG, BETTS RF, McKENNA BA, FREEMAN RB. Antibody Response to Influenza Vaccination in Renal Transplant Patients: Correlation with Allograft Function. Ann Intern Med. ;85:431–436. doi: 10.7326/0003-4819-85-4-431
Download citation file:
Published: Ann Intern Med. 1976;85(4):431-436.
Infectious Disease, Influenza, Nephrology, Prevention/Screening, Renal Replacement Therapy.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use